Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Besse · SciRah

Researcher profile · Semantic Scholar

B. Besse

Share profile

B. Besse — researcher profile on SciRah

h-index: 102
Works: 1,575
Citations: 54K

Most-cited papers

Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
J. Yang, Shun Lu, H. Hayashi, E. Felip +52 more
2025New England Journal of Medicine129 citations
Semantic Scholar
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial
B. Besse, Jessica J. Lin, Lyudmila Bazhenova, Koichi Goto +20 more
2026Nature Medicine25 citations Open access
Semantic Scholar
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration.
A. Dingemans, I. Opitz, A. Brunelli, Jordi Remon +32 more
2026The Lancet Respiratory Medicine13 citations Open access
Semantic Scholar
Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer.
Yi-Long Wu, Maximilian J. Hochmair, Yi Yang, Xue-Ning Yang +15 more
2026New England Journal of Medicine9 citations
Semantic Scholar
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.
L. Brunetti, Valentina Santo, D. Pinato, F. Citarella +26 more
2026The Lancet Oncology7 citations Open access
Semantic Scholar
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies.
M. Aldea, S. Lenahan, Marine Locquet, L. Liao +44 more
2026Annals of Oncology7 citations
Semantic Scholar
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.
H. Hayashi, Byoung Chul Cho, D. Spigel, N. Girard +18 more
2026Journal of Thoracic Oncology6 citations Open access
Semantic Scholar
Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study
M. Wiesweg, S. Gadgeel, B. Cho, S. Lu +42 more
2025Pneumologie6 citations
Semantic Scholar
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer
B. Besse, V. Subbiah, G. Curigliano, Daniel W. Bowles +27 more
2026Journal of Clinical Oncology5 citations Open access
Semantic Scholar
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50%
A. De Giglio, L. Zullo, Alessandro Di Federico, M. Cani +15 more
2025ESMO Open5 citations Open access
Semantic Scholar
ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK + NSCLC.
J. Lin, E. Felip, B. C. Cho, B. Besse +16 more
2026Journal of Clinical Oncology3 citations Open access
Semantic Scholar
Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial.
J. Goldman, Xue-Ning Yang, M. Hochmair, Lin Wu +14 more
2026Journal of Clinical Oncology3 citations Open access
Semantic Scholar
The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib
M. Nagasaka, Francesco Facchinetti, L. Bigot, F. Brayé +11 more
2026npj Precision Oncology2 citations Open access
Semantic Scholar
NSCLC in Vulnerable and Special Populations: Toward Personalized Care.
Claudia Parisi, A. De Giglio, Marco Banini, M. Tagliamento +11 more
2026Journal of Thoracic Oncology2 citations
Semantic Scholar
The interplay of clonal hematopoiesis and cancer: Clinical implications in oncology.
M. Tanguay, M. Tagliamento, J. Samaniego, B. Besse +3 more
2026Cancer Treatment Reviews2 citations
Semantic Scholar
LBA1 Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY
B. Besse, E. Felip, B. Cho, T. Takahashi +16 more
2026ESMO Open2 citations Open access
Semantic Scholar
Single-cell trajectories in metastatic urothelial carcinoma reveal tumor–immune reprogramming and macrophage-driven resistance to PD-(L)1 blockade
R. Flippot, A. Roehrig, Julien Vibert, N. Stransky +21 more
2026bioRxiv1 citations
Semantic Scholar
PRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of-view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol
Margaux Geier, K. Amrane, D. Bourhis, P. Le Roux +15 more
2026PLoS ONE1 citations Open access
Semantic Scholar
Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?
A. Mavrikios, M. Bortolot, C. Le Péchoux, J. Remon +20 more
2026Annals of Oncology1 citations
Semantic Scholar
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.
May-Lucie Meyer, Solange Peters, Hossein Borghaei, T. Cascone +86 more
2026Journal of Thoracic Oncology1 citations Open access
Semantic Scholar
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis
A. Drilon, B. C. Cho, D. Camidge, Misako Nagasaka +17 more
2026The Oncologist1 citations Open access
Semantic Scholar
Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab.
Adrien Rousseau, S. Foulon, D. Planchard, Jordi Remon +12 more
2026JAMA Oncology1 citations
Semantic Scholar
Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer
F. Dall'Olio, W. Zrafi, D. Vasseur, Camilo Garcia +20 more
2026Clinical Cancer Research1 citations Open access
Semantic Scholar
Tumor purity as a prognostic and predictive biomarker of postoperative radiotherapy outcomes in stage IIIA-N2 non-small-cell lung cancer: a transcriptomic analysis from the Lung ART trial.
W. Zrafi, Victor Albarrán-Artahona, F. Dall'Olio, M. Ghigna +8 more
2026International Journal of Radiation Oncology, Biology, Physics1 citations
Semantic Scholar
VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC
M. Roulleaux-Dugage, A. Yurchenko, Sergey I. Nikolaev, B. Nabet +14 more
2026Journal for ImmunoTherapy of Cancer1 citations Open access
Semantic Scholar
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC)
C. Parisi, M. Banini, F. Mantuano, M. Aldea +16 more
2026ESMO Open1 citations Open access
Semantic Scholar
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.
L. Cipriani, Davide Mascolo, S. Scalera, Giulia Bon +24 more
2026Clinical Cancer Research1 citations
Semantic Scholar
PP01.59: ABBIL1TY NSCLC-06: A Global, Randomized, Open-Label, Phase 3 Trial of Acasunlimab in Combination with Pembrolizumab vs Docetaxel in Checkpoint Inhibitor–Experienced Patients with PD-L1+ Metastatic Non-Small Cell Lung Cancer
L. Paz-Ares, B. Besse, Michael Thomas, J. Aerts +14 more
2026Journal of Thoracic Oncology1 citations
Semantic Scholar
Efficacy and safety of pralsetinib as first-line treatment of RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC): The phase 3 AcceleRET-Lung study.
Sanjay Popat, B. Besse, A. Calles, F. Cecere +11 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
Comprehensive characterization of early-stage Non-Small Cell Lung cancers with multi-modal data integration
D. Schulz, M. Morfouace, B. P. Fernandez, M. Możejko +14 more
2025medRxiv1 citations Open access
Semantic Scholar
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.
J. Menis, L. Greiller, P. Demontrond, Isabelle Monnet +30 more
2025European Journal of Cancer1 citations Open access
Semantic Scholar
Radon and lung cancer.
É. Auclin, M. Janin, L. Mezquita, B. Besse
2026Bulletin du Cancer0 citations Open access
Semantic Scholar
PL03.06: Zidesamtinib in TKI-naive Patients with Advanced/Metastatic ROS1+ NSCLC: ARROS-1 Efficacy and Safety Data
A. Drilon, A. D. de Langen, B. Besse, A. Swalduz +40 more
2026Journal of Thoracic Oncology0 citations
Semantic Scholar
P3.187: Treatment Sequences and Outcomes in Patients With ALK/ROS1 Advanced Non-Small Cell Lung Cancer: A Nationwide Cohort Study
A. Rousseau, S. Foulon, P. Lavaud, L. Zullo +14 more
2026Journal of Thoracic Oncology0 citations
Semantic Scholar
560eP Molecular characterization of pulmonary and tracheal adenoid cystic carcinomas
D. Diaz-Jimenez, D. Miliziano, A. Chahbar, E. Sais +15 more
2026ESMO Open0 citations Open access
Semantic Scholar
Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.
M. Tagliamento, M. Bruzzone, E. Blondeaux, F. Dall'Olio +10 more
2026European Journal of Cancer0 citations Open access
Semantic Scholar
Publication of clinical Ttial results: experience of an academic sponsor within the National Open Science Plan
Mathieu Cocheteux, S. Michiels, B. Besse, A. Bayle
2026Journal of Epidemiology and Population Health0 citations
Semantic Scholar
310P Real-world outcomes of chemoradiation (CRT) in stage III, unresectable EGFR-mutant non-small cell lung cancer (NSCLC)
V. Favorito, F. Monaca, M. Cani, J. Cabon +16 more
2026ESMO Open0 citations Open access
Semantic Scholar
ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC.
M. Garassino, S. Cousin, B. Besse, A. Sacher +11 more
2026Clinical Lung Cancer0 citations
Semantic Scholar
Hospital-Compounded Birabresib Capsules for NUT Carcinoma: A Quality- and Risk-Based CMC Strategy
M. Annereau, F.-X. Legrand, M. V. Sanchez-Becerra, Stephanie N. Ramos +7 more
2026Pharmaceutical Research0 citations Open access
Semantic Scholar
P2.102: Clinico-Biological Characteristics and Treatment Outcomes in Patients With RET+ Lung Cancer With non-LUAD Histology
A. Marinello, M. Lomibao, J. Quintanilha, T. Adeyelu +46 more
2026Journal of Thoracic Oncology0 citations
Semantic Scholar
Abstract CT213: A phase I/II study to evaluate EP0031 (lunbotinib), a next-generation selective RET inhibitor, as monotherapy and in combination with chemotherapy, in patients with advanced RET-fusion-positive NSCLC
J. Rubio-Perez, E. Garralda, B. Besse, M. Aldea +23 more
2026Cancer Research0 citations
Semantic Scholar
301P Early access program of birabresib in NUT carcinoma patients
M. V. Sanchez-Becerra, M. Annereau, I. Yoldjan, F. Legrand +10 more
2026ESMO Rare Cancers0 citations Open access
Semantic Scholar
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.
F. Facchinetti, L. Friboulet, L. Liao, M. Peroni +36 more
2026Annals of Oncology0 citations
Semantic Scholar
Impact of immunotherapy on overall survival and healthcare costs in advanced/metastatic lung cancer: A real-world study in France.
A. Rousseau, A. Foix-Colonier, Joelene Luu, S. Foulon +8 more
2026Lung Cancer0 citations
Semantic Scholar
P1.120: Neoadjuvant Single-Dose Atezolizumab in Resectable IA-IIIA NSCLC: Immune-Profiling and Transcriptomic Analyses From Phase 2 PRINCEPS Trial
A. Nuccio, L. Cassard, N. Cozic, M. Ben Salah +16 more
2026Journal of Thoracic Oncology0 citations
Semantic Scholar
P3.142: SENLOAD Study: Association of Baseline CD8 T-Cell Senescence With Survival in Unresectable Stage III NSCLC
J. Benítez, M.-V. Sanchez-Becerra, M. Naigeon, W. Zrafi +14 more
2026Journal of Thoracic Oncology0 citations
Semantic Scholar
109P Patient-reported outcomes with acasunlimab monotherapy and in combination with pembrolizumab: Results from a phase II study of PD-L1+ mNSCLC
J. Aerts, B. Besse, W. Theelen, D. M. Kowalski +8 more
2026ESMO Open0 citations Open access
Semantic Scholar
104P Toxicity patterns associated with sequencing immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs): A nationwide real-world analysis from the French Health Insurance Database (SNDS)
C. Parisi, A. Lolivier, A. Rousseau, S. Foulon +15 more
2026ESMO Open0 citations Open access
Semantic Scholar
14P Prevalence, evolution, management of amivantamab-related AEs in patients with advanced EGFR-mutant NSCLC
B. Napolitano, V. Favorito, C. Genova, M. Gasparro +10 more
2026ESMO Open0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Planchard×17
Invite
D. Planchard — researcher profile on SciRah
M. Aldea×11
Invite
M. Aldea — researcher profile on SciRah
P. Lavaud×9
Invite
P. Lavaud — researcher profile on SciRah
A. Drilon×7
Invite
A. Drilon — researcher profile on SciRah

×7

Invite

L. Paz-Ares — researcher profile on SciRah

C. Le Péchoux×7

Invite

C. Le Péchoux — researcher profile on SciRah

Invite

E. Felip — researcher profile on SciRah

A. Botticella×6

Invite

A. Botticella — researcher profile on SciRah

F. Dall'Olio×5

Invite

F. Dall'Olio — researcher profile on SciRah

Invite

M. Aldea — researcher profile on SciRah

Invite

M. Frélaut — researcher profile on SciRah

Invite

W. Zrafi — researcher profile on SciRah